Original Research

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?

Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Shor A, Tremblay G

Cancer Management and Research 2018, 10:1015-1025

Published Date: 4 May 2018